Navigation Links
'Alarming' Rise Seen in Drug-Resistant Tuberculosis
Date:8/30/2012

THURSDAY, Aug. 30 (HealthDay News) -- There are alarmingly high levels of extensively drug-resistant tuberculosis in many areas of the world, a new study finds.

Researchers found high rates of resistance to at least one second-line drug (nearly 44 percent) among multidrug-resistant TB patients in eight countries in Africa, Asia, Europe and Latin America. They also found higher-than-expected overall levels of extensively drug-resistant TB.

Multidrug-resistant TB can withstand to at least two first-line drugs: soniazid and rifampicin. Extensively drug-resistant TB is resistant to isoniazid, rifampicin, a fluoroquinolone and a second-line injectable drug.

Fluoroquinolones are a class of antibiotics that include ciprofloxacin, levofloxacin and gatifloxacin.

For the study, samples collected from nearly 1,300 adults with multidrug-resistant TB in Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea and Thailand were tested for resistance to 11 first-line and second-line anti-TB drugs. Overall, in nearly 44 percent of patients, resistance to any second-line drug was detected. Rates ranged from 33 percent in Thailand to 62 percent in Latvia.

Overall, one-fifth of patients had resistance to at least one second-line injectable drug, ranging from 2 percent in the Philippines to 47 percent in Latvia. The overall rate of resistance to a fluoroquinolone was nearly 13 percent, ranging from 7 percent in the Philippines to 32 percent in South Korea.

Extensively drug-resistant TB was found in 6.7 percent of patients overall, with prevalence in South Korea (15 percent) and Russia (11 percent) more than twice the current World Health Organization estimate for the same time period (5.4 percent).

The researchers also found that the risk of extensively drug-resistant TB was more than four times higher in patients previously treated for TB, and that previous treatment with second-line drugs was the strongest risk factor for resistance.

The study was published online Aug. 29 in The Lancet.

"Drug-resistant TB is more difficult and costly to treat, and more often fatal. Internationally, it is particularly worrisome in areas with fewer resources and less access to effective therapies. As more individuals are diagnosed with, and treated for, drug-resistant TB, more resistance to second-line drugs is expected to emerge," lead author Tracy Dalton, of the U.S. Centers for Disease Control and Prevention, said in a journal news release.

"So far, [extensively drug-resistant] TB has been reported in 77 countries worldwide, but exact prevalence remains unclear," Dalton noted.

"Most international recommendations for TB control have been developed for [multidrug-resistant] TB prevalence of up to around 5 percent. Yet now we face prevalence up to 10 times higher in some places, where almost half of the patients with infectious disease are transmitting [multidrug-resistant] strains," Sven Hoffner, from the Swedish Institute for Communicable Disease Control, wrote in an accompanying journal editorial.

"Updated information on [multidrug-resistant] TB and investigation of the trends are urgently needed...especially since the true scale of the burden of [multidrug-resistant] and [extensively drug-resistant tuberculosis] might be underestimated and seem to be rapidly increasing," he wrote.

More information

The U.S. Centers for Disease Control and Prevention has more about TB.

-- Robert Preidt

SOURCE: The Lancet, news release, Aug. 29, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. African Chimps Carry Drug-Resistant, Human-Linked Staph
2. Computational analysis identifies drugs to treat drug-resistant breast cancer
3. Scientists develop new strategy to overcome drug-resistant childhood cancer
4. Rare Drug-Resistant Bacteria Spotted in U.S. Hospital
5. New Medicine Might Fight Drug-Resistant TB, Study Says
6. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
7. Kinase test may yield big gains for drug-resistant cancers
8. Dartmouth medical research closes in on new tuberculosis vaccine
9. Tuberculosis increases the risk of lung cancer mortality in the elderly
10. A better tool to diagnose tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Alarming' Rise Seen in Drug-Resistant Tuberculosis 
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Love is ... roses in a variety of colors, assortments and packaging. This staple for Valentine’s Day ... King Kullen location. , For Valentine’s Day, not only are long-stem roses available, ...
(Date:2/5/2016)... Falls, NY & Salt Lake City, UT (PRWEB) , ... February ... ... Davis, Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with ... on the New Really Cool Humans Amateur TV Network. , Each week, on his ...
(Date:2/5/2016)... ... ... The event is being held on April 7, 2016 from 5:30 p.m. to ... will fund nearly $100,000 for research for the care and cure of Parkinson’s disease. ... the architect of this informative event to raise awareness and funds for Parkinson’s. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco ... micro-needling services in their Napa Valley office. The technique utilizes the body’s own ... Dr. Canales and Dr. Furnas, are part of only a select few cosmetic ...
(Date:2/5/2016)... Dickson, Tennessee (PRWEB) , ... February 05, 2016 ... ... State Community College President George H. Van Allen have signed a joint enrollment ... semester, provides a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)...  Montoya Love is recognized by Continental Who,s Who ... Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range of ... healthcare institutions, clinical laboratories and life science researchers with ... globe. ...
(Date:2/4/2016)... 2016  Omnicell, Inc. (NASDAQ: OMCL ), a leading ... systems, today announced results for its fiscal year and ... --> GAAP results: Revenue for the ... million or 4.1% from the third quarter of 2015, ... quarter of 2014. Revenue for the year ended December 31, ...
(Date:2/4/2016)... , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) today ... of Pfizer Inc. and President of Pfizer Global Supply, has ... of February 4, 2016. In addition, the Company announced that ... the audit committee since 2010, has retired from the AMRI ... attention to his other business ventures.  William ...
Breaking Medicine Technology: